StreetInsider.com News Articles

Form SCHEDULE 13G/A CervoMed Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26932117.html

Form SCHEDULE 13G/A CervoMed Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26932117.html

Form SCHEDULE 13G/A CervoMed Inc. Filed by: CVI Investments, Inc.

Fri, 14 Aug 2026 14:42:00 -0400

si-local-file:///var/storage/secattach/20260814/26929129.html

Form SCHEDULE 13G/A CervoMed Inc. Filed by: CVI Investments, Inc.

Fri, 14 Aug 2026 14:42:00 -0400

si-local-file:///var/storage/secattach/20260814/26929129.html

Form SCHEDULE 13G CervoMed Inc. Filed by: Woodline Partners LP

Fri, 14 Aug 2026 11:03:00 -0400

si-local-file:///var/storage/secattach/20260814/26927031.html

Form SCHEDULE 13G CervoMed Inc. Filed by: Woodline Partners LP

Fri, 14 Aug 2026 11:03:00 -0400

si-local-file:///var/storage/secattach/20260814/26927031.html

Form SCHEDULE 13G CervoMed Inc. Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26926160.html

Form SCHEDULE 13G CervoMed Inc. Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26926160.html

CervoMed (CRVO) PT Lowered to $12 at Jones Trading

Mon, 10 Aug 2026 16:36:13 -0400

Jones Trading analyst Boris Peaker lowered the price target on CervoMed (NASDAQ: CRVO) to $12.00 (from $20.00) while maintaining a Buy rating.

Form 8-K CervoMed Inc. For: Aug 10

Mon, 10 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260810/26897867.html

Form 8-K CervoMed Inc. For: Aug 10

Mon, 10 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260810/26897867.html

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Mon, 10 Aug 2026 07:30:00 -0400

Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB)

Neflamapimod awarded Innovation Passport Designation under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP) for development in DLB

New analyses presented at the Alzheimer’s Association International Conference (AAIC) 2026 reinforce neflamapimod's treatment effect in pure DLB and support 50 mg TID dose for planned Phase 3 trial

Initial, 12-week biomarker data from Phase 2a clinical trial in nonfluent variant primary progressive aphasia (nfvPPA) to be presented at the 15^th International Conference on Frontotemporal Dementia

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Mon, 10 Aug 2026 07:30:00 -0400

Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB)

Neflamapimod awarded Innovation Passport Designation under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP) for development in DLB

New analyses presented at the Alzheimer’s Association International Conference (AAIC) 2026 reinforce neflamapimod's treatment effect in pure DLB and support 50 mg TID dose for planned Phase 3 trial

Initial, 12-week biomarker data from Phase 2a clinical trial in nonfluent variant primary progressive aphasia (nfvPPA) to be presented at the 15^th International Conference on Frontotemporal Dementia

CervoMed (CRVO) PT Lowered to $18 at Canaccord

Mon, 10 Aug 2026 07:29:40 -0400
(Updated - August 10, 2026 7:29 AM EDT)
Canaccord analyst Sumant Kulkarni lowered the price target on CervoMed (NASDAQ: CRVO) to $18.00 (from $27.00) while maintaining a Buy rating.
The analyst commented: "CRVO recently announced that the United Kingdom (UK) has awarded the company's lead candidate, neflamapimod, an Innovation Passport under the UK Innovative Licensing and Access Pathway (ILAP) for the treatment of dementia with Lewy bodies (DLB). We view this designation, which is now highly selective, as robust and independent external validation of the product's immense potential in DLB. Recall CRVO has reached regulatory alignment on a Phase 3 design. So,

CervoMed (CRVO) PT Lowered to $18 at Canaccord

Mon, 10 Aug 2026 07:29:40 -0400
(Updated - August 10, 2026 7:29 AM EDT)
Canaccord analyst Sumant Kulkarni lowered the price target on CervoMed (NASDAQ: CRVO) to $18.00 (from $27.00) while maintaining a Buy rating.
The analyst commented: "CRVO recently announced that the United Kingdom (UK) has awarded the company's lead candidate, neflamapimod, an Innovation Passport under the UK Innovative Licensing and Access Pathway (ILAP) for the treatment of dementia with Lewy bodies (DLB). We view this designation, which is now highly selective, as robust and independent external validation of the product's immense potential in DLB. Recall CRVO has reached regulatory alignment on a Phase 3 design. So,

Form S-8 CervoMed Inc.

Fri, 07 Aug 2026 16:55:00 -0400
si-local-file:///var/storage/secattach/20260807/26891940.html

Form S-8 CervoMed Inc.

Fri, 07 Aug 2026 16:55:00 -0400
si-local-file:///var/storage/secattach/20260807/26891940.html

Form 10-Q CervoMed Inc. For: Jun 30

Fri, 07 Aug 2026 16:27:00 -0400
si-local-file:///var/storage/secattach/20260807/26891467.html

Form 10-Q CervoMed Inc. For: Jun 30

Fri, 07 Aug 2026 16:27:00 -0400
si-local-file:///var/storage/secattach/20260807/26891467.html

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

Wed, 05 Aug 2026 07:30:00 -0400

BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference, being held in Boston, MA, on Tuesday, August 11, 2026.

During the fireside chat, management will share recent progress in neflamapimod's clinical development program.

Presentation Details
Format: Fireside Chat
Date: Tuesday, August 11, 2026
Time: 11:30 – 11:55 AM ET
Webcast Link: https://event.summitcast.com/view/WuFmFdTcA9mVsUGHZJFU62/guest_book?session_id=CbcwtmiHhUmzr5EAgGgHjJ

The webcast of

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

Wed, 05 Aug 2026 07:30:00 -0400

BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference, being held in Boston, MA, on Tuesday, August 11, 2026.

During the fireside chat, management will share recent progress in neflamapimod's clinical development program.

Presentation Details
Format: Fireside Chat
Date: Tuesday, August 11, 2026
Time: 11:30 – 11:55 AM ET
Webcast Link: https://event.summitcast.com/view/WuFmFdTcA9mVsUGHZJFU62/guest_book?session_id=CbcwtmiHhUmzr5EAgGgHjJ

The webcast of

Form 8-K CervoMed Inc. For: Aug 04

Tue, 04 Aug 2026 07:52:00 -0400
si-local-file:///var/storage/secattach/20260804/26861734.html

Form 8-K CervoMed Inc. For: Aug 04

Tue, 04 Aug 2026 07:52:00 -0400
si-local-file:///var/storage/secattach/20260804/26861734.html

CervoMed's neflamapimod receives UK innovation passport for DLB

Tue, 04 Aug 2026 06:00:06 -0400

CervoMed Inc. (NASDAQ: CRVO) announced that its drug candidate neflamapimod has been granted an Innovation Passport under the UK's Innovative Licensing and Access Pathway (ILAP) for the treatment of dementia with Lewy bodies (DLB).
The designation provides CervoMed with coordinated guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA), the National Health Service (NHS), and health technology assessment bodies including the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), the All Wales Therapeutics and Toxicology Centre (AWTTC), and the Department of Health Northern Ireland.
The company said the ILAP entry criteria were revised in early

CervoMed's neflamapimod receives UK innovation passport for DLB

Tue, 04 Aug 2026 06:00:06 -0400

CervoMed Inc. (NASDAQ: CRVO) announced that its drug candidate neflamapimod has been granted an Innovation Passport under the UK's Innovative Licensing and Access Pathway (ILAP) for the treatment of dementia with Lewy bodies (DLB).
The designation provides CervoMed with coordinated guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA), the National Health Service (NHS), and health technology assessment bodies including the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), the All Wales Therapeutics and Toxicology Centre (AWTTC), and the Department of Health Northern Ireland.
The company said the ILAP entry criteria were revised in early